Evaluating the Economic Impact of Whole Genome Sequencing (WGS) in Patients with Rare and Undiagnosed Genetic Diseases

Tuesday, November 06, 2018
Evaluating the Economic Impact of Whole Genome Sequencing (WGS) in Patients with Rare and Undiagnosed Genetic Diseases
Tuesday, November 06, 2018 11:00 AM - 12:00 PM (Pacific Time)


Description of Program Content:

An emerging body of evidence is providing support for the use of whole genome sequencing (WGS) early in the diagnostic trajectory of patients with suspected genetic diseases, with studies demonstrating both high diagnostic utility and clinical utility. As the clinical evidence continues to grow, it is important to evaluate the economic impact of clinical WGS. In this webinar, we will review the current evidence evaluating the economic utility of WGS in clinical care, discuss the strengths and weaknesses of current data, and share an economic model we have developed to project the economic impact within a defined healthcare system.


Measurable Learning Objectives 
At the end of this activity the participant will be able to:

1. Discuss the published evidence evaluating the economic utility of WGS in patients with undiagnosed suspected genetic diseases
2. Discuss the strengths and weaknesses of existing published economic data, key challenges, and critical areas for future evidence development


Presenter:  Brock Schroeder, PhD, Director, Health Economics & Outcomes Research, Illumina, Inc.
BIO
Brock Schroeder is Director of Health Economic & Outcomes Research (HEOR) at Illumina.  In this position, Brock oversees Global HEOR and Market Access Strategic Plans in support of existing and new clinical applications of next generation sequencing (NGS). Prior to joining Illumina, Brock led Medical Affairs at Biotheranostics, Inc, where his team was responsible for generating evidence supporting the clinical utility and economic utility of 2 proprietary molecular diagnostic tests in the oncology therapeutic area, as well as engaging with academic researchers and payers on the value of the tests to patients and healthcare systems. Brock’s industry experience includes multiple therapeutic areas, including oncology, endocrinology, nephrology, and neurology, and has included both pharmaceuticals and molecular diagnostics. Brock has authored or co-authored 25 peer-reviewed manuscripts and more than 50 scientific congress abstracts. He received his BA in Biology from Washington University in St. Louis, and his PhD in Neuroscience from University of Wisconsin-Madison.







 

Contact Information

Payment Instructions

  • Credit Cards Accepted

    Please make checks out to
    :
    Medical Training Solutions, Inc. 
     
    Please address Check to:

    MTS
    ATTN: Laboratory Webinars
    PO Box 17349
    Seattle, WA 98127

    PO Requests:
    Email: support@medtraining.org 

    Thank You!!
© 2019
Quick, easy and affordable online event registration and event management software for all event sizes.